Clinically Lymph Node Positive Prostate Cancer: At the Intersection of Focal and Systemic Disease Control.

Clinically Lymph Node Positive Prostate Cancer: At the Intersection of Focal and Systemic Disease Control. Cancer J. 2020 Jan/Feb;26(1):53-57 Authors: Reichert ZR, Dess RT Abstract Clinically node-positive prostate cancer is often found at the time of diagnosis by cross-sectional imaging and remains poorly understood. Advanced imaging modalities such as magnetic resonance imaging nanoparticles or positron emission tomography-based molecular imaging stand to rapidly change the field and hopefully will bring better diagnostic clarity. This will allow for prospective clinical trials using radiographic, clinical, or molecular parameters to establish who may benefit from both localized and systemic treatment intensification and who may avoid overtreatment. Recent advances in metastatic hormone-sensitive disease may offer clues, but direct studies for nodal disease patients remain. PMID: 31977386 [PubMed - in process]
Source: Cancer Journal - Category: Cancer & Oncology Authors: Tags: Cancer J Source Type: research

Related Links:

Publication date: Available online 31 March 2020Source: Actas Urológicas Españolas (English Edition)Author(s): D. Nieblas-Toscano, A.J. Arenas-Bonilla, J.F. Flores-Martín, F. Gutiérrez-Tejero, C. Velarde-Muñoz, C.I. Ramos-Alaminos, M.C. Salas-Moreno, R. Galisteo-Moya, J. Moreno-Jiménez
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancerOral androgen receptor inhibitor (ARi) Nubeqa® (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profilemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Authors: Ahmadianpour MV, Mowla J, Sotoodehnejadnematalahi F, Raheb J Abstract Studies on the blood of patients with prostate cancer using Dynamic Light Scattering (DLS) and corona protein size changes have shown that this test is highly specific and sensitive, but this method has not been studied in Iran, and therefore this study intends to perform this procedure using gold nanoparticles in prostate cancer detection. Blood samples of 60 male subjects aged 40-90 years were collected from 20 healthy, 20 benign and 20 prostate cancer patients. Optical scattering changes were measured by the level of gold nanoparticle...
Source: Human Antibodies - Category: Biochemistry Tags: Hum Antibodies Source Type: research
Conditions:   Breast Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Metastatic Prostate Cancer Interventions:   Behavioral: In Person Counseling;   Behavioral: Educational Video Sponsors:   Dana-Farber Cancer Institute;   Ambry Genetics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We present a case of a 79 year old patient with a medical history of unilateral nerve-sparing radical prostatectomy due to a pT3aN0 (Gleason score 7) prostate carcinoma. Because of slightly elevated prostate specific antigen (PSA) level (0.35ng/dL), a fluorine-18-prostate specific membrane antigen (18F-PSMA)-1007 positron emission tomography/computed tomography (PET/CT) scan was performed, showing no signs of malignant recurrence. However, a moderately PSMA-avid nodular lesion was observed in the left occipital region with homogeneous contrast enhancement, suggestive for a meningioma, which was confirmed on magnetic resona...
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
CONCLUSION: Carbon-11-choline PET was found have a greater correlation with Gleason score than DWI and is considered to be more useful to predict a higher score in patients with prostate cancer. Fluorine-18-FDG PET was limited because of low sensitivity. PMID: 32222730 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
Authors: Frantellizzi V, De Feo MS, Di Rocco A, Pontico M, Pani A, Farcomeni A, Cosma L, Lazri J, De Vincentis G Abstract OBJECTIVE: The prognostic value of baseline clinical parameters in predicting the survival prolonging effect of radium-223-dichloride (223Ra)-therapy in metastatic castration resistant prostate cancer (mCRPC) patients is still an open issue. The aim of this study was investigating the impact of baseline quality of life (QoL) on overall survival (OS) in mCRPC patients treated with 223Ra. The present study also evaluated the trend of patient-reported QoL during both 223Ra-treatment and post-therap...
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
Purpose of review Patients with nonmuscle invasive bladder cancer (NMIBC) have a high risk of recurrent tumors, even in spite of contemporary guideline recommended therapy. Follow-up recommendations are also clear (cystoscopy with cytology and upper urinary tract imaging in high-risk patients), but frequency and duration of follow-up are well defined. However, recent developments in follow-up tools might be of interest for clinical practice. Recent findings Enhanced endoscopy improves detection and treatment of recurrences, and it can help in tailoring follow-up. However, it remains an invasive procedure. Most recentl...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: BLADDER CANCER: Edited by Juan Palou and Óscar Rodríguez Faba Source Type: research
Conclusion: This study has shown that simplification of ISH protocols by the use of COPs provides equivalent results to the use of LNA methods and it can be used to precisely identify cells in which miRNAs are expressed. PMID: 32223721 [PubMed - as supplied by publisher]
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
Contributors : Junhang Luo ; Zhiping LiuSeries Type : Expression profiling by high throughput sequencing ; Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensWe studied the alternative splicing function of KDM4B and found that KDM4B can act as a bona fide trans-acting splicing factor that binds RNA and signal-responsive scaffold protein that binds spliceosome.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Hormones | MRI Scan | Nanotechnology | PET Scan | Prostate Cancer | Radiography | Study